TiGenix Priced, Nasdaq: TIG

Developing injectable stem cell therapies for the treatment of perianal fistulas.

Industry: Health Care

Latest Trade: $23.73 0.00 (0.0%)

First Day Return: -24.5%

Return from IPO: +53.1%

Industry: Health Care

We are an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells. We have completed, and received positive data in, a single pivotal Phase III trial in Europe and Israel of our most advanced product candidate Cx601, a first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. A complex perianal fistula consists of abnormal tracts between the rectum and the exterior surroundings of the anus, and is commonly associated with Crohn's disease. It is a serious clinical condition affecting the anal sphincter and is potentially associated with a perianal abscess. Cx601 has been granted orphan designation by the European Medicines Agency, or EMA, in recognition of its potential application for the treatment of anal fistulas, which affect approximately 120,000 adult patients in the United States and Europe and for which existing treatment options are inadequate. The EMA grants orphan designation to medicinal products for indications that affect no more than five out of 10,000 people in the European Union. The benefits of orphan designation include a streamlined process for obtaining relevant regulatory approvals and up to ten years of exclusivity in the European market.
more less
IPO News for TiGenix
more
IPO Data
IPO File Date 12/22/2015
Offer Price $15.50
Price Range $15.50 - $15.50
Offer Shares (mm) 2.3
Deal Size ($mm) $36
IPO Data
IPO Date 12/14/2016
Offer Price $15.50
Price Range $15.50 - $15.50
Offer Shares (mm) 2.3
Deal Size ($mm) $36
Underwriters
more
Company Data
Headquarters Leuven, Belgium
Founded 2000
Employees 74
Website www.tigenix.com